According to the latest report by IMARC Group “Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027.
Hemophilia is a rare inherited bleeding disorder that hampers the blood clotting ability of the body due to the lack of factor VIII, the blood-clotting protein. It can lead to serious health ailments, such as headaches, anemia, conjunctivitis, stomach aches, and mononucleosis. Hemophilia can be treated through clot-preserving medications, fibrin sealants, desmopressin, and vaccination. There are different lifestyle modifications that can also help in treating hemophilia, such as regular exercise and usage of protective gear to prevent injuries.
Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Numerous initiatives undertaken by the governments of different nations for funding the research and development (R&D) of newer treatment methods are primarily driving the global hemophilia market. The escalating prevalence of hemophilia, rising diagnosis rate and the widespread adoption of prophylactic treatment for hemophilia are propelling the market growth. Furthermore, the rapid establishment welfare organizations, such as the National Hemophilia Foundation (NHF) of the United States (US), and World Federation of Hemophilia (WFH), are creating a positive outlook in the market across the globe.
Breakup by Type:
- Hemophilia A
- Hemophilia B
- Hemophilia C
Breakup by Treatment:
Breakup by Therapy:
- Replacement Therapy
- ITI Therapy
- Gene Therapy
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Baxter International Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- CSL Behring (CSL Limited)
- F. Hoffmann-La Roche AG
- Grifols S.A.
- Kedrion S.p.A.
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited.
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/hemophilia-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800